114 related articles for article (PubMed ID: 26901163)
1. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Kudo M; Lencioni R; Marrero JA; Venook AP; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Ye SL
Liver Int; 2016 Aug; 36(8):1196-205. PubMed ID: 26901163
[TBL] [Abstract][Full Text] [Related]
2. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Lencioni R; Marrero J; Venook A; Ye SL; Kudo M
Int J Clin Pract; 2010 Jul; 64(8):1034-41. PubMed ID: 20642705
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea.
Han S; Kim DY; Lim HY; Yoon JH; Ryoo BY; Kim Y; Kim K; Kim BY; Yi SY; Kim DS; Cho DY; Yu J; Kim S; Park JW
Gut Liver; 2024 Jan; 18(1):116-124. PubMed ID: 37334671
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
Yoo SY; Badrinath N; Woo HY; Heo J
Mediators Inflamm; 2017; 2017():5198798. PubMed ID: 28512387
[TBL] [Abstract][Full Text] [Related]
5. The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation.
Song P; Tang W; Tamura S; Hasegawa K; Sugawara Y; Dong J; Kokudo N
Biosci Trends; 2010 Dec; 4(6):283-7. PubMed ID: 21248425
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan.
Lin YJ; Lin CN; Sedghi T; Hsu SH; Gross CP; Wang JD; Wang SY
PLoS One; 2020; 15(10):e0240542. PubMed ID: 33052942
[TBL] [Abstract][Full Text] [Related]
7. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US.
Stacy S; Hyder O; Cosgrove D; Herman JM; Kamel I; Geschwind JF; Gurakar A; Anders R; Cameron A; Pawlik TM
J Gastrointest Surg; 2013 Sep; 17(9):1600-8. PubMed ID: 23780638
[TBL] [Abstract][Full Text] [Related]
8. The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL).
Okushin K; Tateishi R; Hirakawa S; Tachimori H; Uchino K; Nakagomi R; Yamada T; Nakatsuka T; Minami T; Sato M; Fujishiro M; Hasegawa K; Eguchi Y; Kanto T; Yoshiji H; Izumi N; Kudo M; Koike K
Sci Rep; 2024 Feb; 14(1):2826. PubMed ID: 38310156
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.
Sim YK; Chong MC; Gandhi M; Pokharkar YM; Zhu Y; Shi L; Lequn L; Chen CH; Kudo M; Lee JH; Strasser SI; Chanwat R; Chow PKH;
Liver Cancer; 2024 Jun; 13(3):298-313. PubMed ID: 38756144
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines.
Feliu J; Sastre J; Maurel J; Isla D
Clin Transl Oncol; 2011 Aug; 13(8):536-44. PubMed ID: 21821487
[TBL] [Abstract][Full Text] [Related]
11. Update on new approaches in the management of hepatocellular carcinoma.
Cabibbo G; Antonucci M; Genco C
Hepat Med; 2010 Nov; 2():163-73. PubMed ID: 24367214
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study.
Moon AM; Cook S; Swier RM; Sanoff HK; Kappelman MD; Wagner LI; Barritt AS; Singal AG; Shah ND; Mauro DM; Yanagihara TK; Gerber DA; Fried MW; Brown C; Waheed M; Teal R; Evon DM
Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37930127
[TBL] [Abstract][Full Text] [Related]
13. The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study.
Murai K; Hikita H; Kodama T; Kaibori M; Nishimura Y; Tatsumi T; Yamada T; Kanto T; Mochida S; Takehara T
Hepatol Res; 2024 May; 54(5):439-450. PubMed ID: 37983632
[TBL] [Abstract][Full Text] [Related]
14. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update.
Kudo M
Liver Cancer; 2021 Jun; 10(3):167-180. PubMed ID: 34239807
[No Abstract] [Full Text] [Related]
15. Management of Hepatocellular Carcinoma in Japan as a World-Leading Model.
Kudo M
Liver Cancer; 2018 May; 7(2):134-147. PubMed ID: 29888204
[No Abstract] [Full Text] [Related]
16. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Marrero JA; Kudo M; Venook AP; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JH; de Guevara LL; Papandreou C; Takayama T; Sanyal AJ; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
J Hepatol; 2016 Dec; 65(6):1140-1147. PubMed ID: 27469901
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
[TBL] [Abstract][Full Text] [Related]
18. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
[TBL] [Abstract][Full Text] [Related]
19. Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry.
Geschwind JF; Gholam PM; Goldenberg A; Mantry P; Martin RC; Piperdi B; Zigmont E; Imperial J; Babajanyan S; Foreman PK; Cohn A
Liver Cancer; 2016 Feb; 5(1):37-46. PubMed ID: 26989658
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
